-- 全美獨立企業聯合會（NFIB）發布的月度小型企業樂觀指數從2月份的98.8和2025年3月的97.4降至3月份的95.8，創下自2025年4月以來的最低點。 NFIB首席經濟學家比爾鄧克爾伯格表示：「《工薪家庭減稅法案》中的20%小企業稅收抵免和其他支持小企業的稅收條款對小企業主來說有很多利好因素。然而，油價的急劇上漲令消費者和企業主都感到恐慌。小企業主不得不承擔這些更高的投入成本，並將其轉嫁給消費者。」 10項組成指標中有8項環比下降，其餘2項維持不變。 獲利趨勢降幅最大，下降11個百分點至淨-25%，而經濟預期下降7個百分點至淨-11%。 淨正值表示預期成長的受訪者多於預期下降的受訪者，反之亦然。 此外，擴張計畫（淨下降 11%）、目前庫存（淨下降 5%）、庫存成長計畫（淨下降 5%）、資本支出計畫（淨下降 16%）、銷售預期（淨下降 7%）和目前職缺（淨下降 32%）的讀數均略有下降。 就業計畫（淨下降 12%）和預期信貸狀況（淨下降 5%）的讀數保持不變。
Related Articles
Asia
Oneview Healthcare Reports Decline in Q1 Cash Receipts From Customers; Shares Up 3%
Oneview Healthcare (ASX:ONE) reported cash receipts from customers of about 3.3 million euros for the first quarter, compared with 4.2 million euros a year earlier, according to a Monday filing with the Australian bourse.The company noted that the year-ago figure includes two large customer receipts totaling more than 2 million euros, which were due to be received during the fourth quarter of 2024 but were received in early 2025.Oneview Healthcare ended March with a cash balance of AU$17.1 million, up from AU$8.1 million at the close of 2025, per the filing.The company's shares gained 3% in recent Monday trade.
$ASX:ONE
Asia
Paradigm to Advance Participants Through Day 112 Follow-Up Period in Phase Three Knee Osteoarthritis Trial, Shares Reach One-Year Low
Paradigm Biopharmaceuticals (ASX:PAR) is set to progress participants through the day 112 follow-up period for the phase three trial evaluating injectable pentosan polysulfate sodium for the treatment of pain associated with knee osteoarthritis in the June quarter, which is required for inclusion in the interim analysis dataset, according to a Monday Australian bourse filing.The independent statistical analysis results for the data set are expected around August. Timing remains subject to the scheduling and review processes of independent third parties, and there is a reasonable likelihood that final interim outcomes may extend into September, it cautioned.The interim analysis is expected to provide the first phase three evaluation of efficacy and safety for injectable pentosan polysulfate sodium in knee osteoarthritis. Primary endpoint top-line results are expected in the March 2027 quarter.Its shares fell 14% in recent trading on Monday, reaching their lowest point in over a year.
$ASX:PAR
Asia
Sanan Optoelectronics Q1 Profit Down 68%, Revenue Slides 33%
Sanan Optoelectronics (SHA:600703) posted first-quarter attributable net profit of 67.5 million yuan, down 68% from 211.9 million yuan the previous year.Earnings per share declined to 0.01 yuan from 0.04 yuan, according to a weekend filing with the Shanghai bourse.Operating revenue declined 33% year over year to 2.91 billion yuan from 4.31 billion yuan.Shares of the software company declined 2% in recent trade.
$SHA:600703